Outset Medical, Inc. (NASDAQ:OM) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Outset Medical, Inc. (NASDAQ:OM) have been given an average rating of “Moderate Buy” by the five research firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have given a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $10.00.

A number of brokerages have issued reports on OM. Wall Street Zen lowered shares of Outset Medical from a “hold” rating to a “sell” rating in a report on Sunday, February 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Outset Medical in a research note on Monday, December 29th. Stifel Nicolaus reduced their price target on Outset Medical from $14.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, January 7th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $7.00 price objective on shares of Outset Medical in a report on Wednesday, December 17th. Finally, BTIG Research cut their price objective on Outset Medical from $17.00 to $15.00 and set a “buy” rating on the stock in a research report on Thursday, February 12th.

Insider Buying and Selling at Outset Medical

In other Outset Medical news, General Counsel John L. Brottem sold 9,314 shares of the stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $5.12, for a total value of $47,687.68. Following the transaction, the general counsel owned 36,957 shares of the company’s stock, valued at approximately $189,219.84. This represents a 20.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Marc Nash sold 5,375 shares of Outset Medical stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $5.12, for a total transaction of $27,520.00. Following the transaction, the executive vice president owned 42,785 shares in the company, valued at approximately $219,059.20. This trade represents a 11.16% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 34,438 shares of company stock worth $172,938. Insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Outset Medical

Institutional investors have recently bought and sold shares of the business. BML Capital Management LLC purchased a new position in Outset Medical during the 4th quarter worth approximately $2,015,000. Pura Vida Investments LLC lifted its holdings in shares of Outset Medical by 8,482.4% in the 2nd quarter. Pura Vida Investments LLC now owns 429,120 shares of the company’s stock valued at $8,243,000 after buying an additional 424,120 shares during the period. Assenagon Asset Management S.A. purchased a new stake in shares of Outset Medical in the third quarter worth about $5,324,000. Geode Capital Management LLC grew its holdings in Outset Medical by 955.9% during the second quarter. Geode Capital Management LLC now owns 415,552 shares of the company’s stock worth $7,984,000 after acquiring an additional 376,196 shares during the period. Finally, Millennium Management LLC grew its holdings in Outset Medical by 165.8% during the third quarter. Millennium Management LLC now owns 421,409 shares of the company’s stock worth $5,950,000 after acquiring an additional 262,874 shares during the period.

Outset Medical Price Performance

OM stock opened at $3.47 on Thursday. The firm has a 50 day moving average of $4.36 and a 200-day moving average of $9.10. The firm has a market capitalization of $63.54 million, a P/E ratio of -0.51 and a beta of 2.08. Outset Medical has a 12 month low of $3.10 and a 12 month high of $21.98. The company has a current ratio of 6.67, a quick ratio of 5.77 and a debt-to-equity ratio of 0.76.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.